IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Inhibition of Major Histocompatibility Complex (MHC)-Restricted Presentation of Exogenous Antigen in Dendritic Cells by Korean Propolis Components

  • Published : 2005.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Dendritic cells (DCs) playa critical role not only in the initiation of immune responses, but also in the induction of immune tolerance. In an effort to regulate immune responses through the modulation of antigen presenting cell (APC) function of DCs, we searched for and characterized APC function modulators from natural products. Methods: DCs were cultured in the presence of propolis components, WP and CP, and then examined for their ability to present exogenous antigen in association with major histocompatibility complexes (MHC). Results: WP and CP inhibited class I MHC-restricted presentation of exogenous antigen (cross-presentation) in a DC cell line, DC2.4 cells, and DCs generated from bone marrow cells with GM-CSF and IL-4. The inhibitory activity of WP and CP appeared to be due not only to inhibition of phagocytic activity of DCs, but also to suppression of expression of MHC molecules on DCs. We also examined the effects of WP and CP on T cells. Interestingly, WP and CP increased IL-2 production from T cells. Conclusion: These results demonstrate that WP and CP inhibit MHC-restricted presentation of exogenous antigen through down-regulation of phagocytic activity and suppression of expression of MHC molecules on DCs.

Keywords

References

  1. Saho U, Haruka F, Chie H, Masatoshi N, Mutsuhiko M: M class I-mediated exogenous antigen presentation by exosom secreted from immature and mature bone marrow deriv dendritic cells. Immunology Letters 89;125-131, 2003 https://doi.org/10.1016/S0165-2478(03)00128-7
  2. Inaba K, lnaba M, Romani N, Ava H, Dezuchi M, Ikeh S, Muramatsu S, Steinman RM: Generation of large numb of dendritic cells from mouse bone marrow cultures supp mented with granulocyte/macrophage colony-stimulating tor. J Exp Med 176;1693-1702, 1992 https://doi.org/10.1084/jem.176.6.1693
  3. Shen Z, Reznikoff G, Dranoff G, Rock KL: Cloned dendr cells can present exogenous antigens on both MHC clas and class II molecules. J Immunol 15;2723-2730, 1997
  4. Zitvozel L, Reanault A, Lozier A, Wolfers J, Flament C, T za D, Ricciardi-Castagnoli P, Raposo G, Arnizorena S: Era cation of established murine tumors using a novel cell-f vaccine: dendritic cell-derived exosomes. Nat Med 4;594-600 1998 https://doi.org/10.1038/nm0598-594
  5. Avigan DD: Dendritic cells: development, function and tential use for cancer immunotherapy. Blood Reviews 13;51-64, 1999 https://doi.org/10.1016/S0268-960X(99)90023-1
  6. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, LD Jr: Peptide-pulsed dendritic cells induce antizen-speci CTL-mediated protective tumor immunity. J Exp Med 183;283-287, 1996 https://doi.org/10.1084/jem.183.1.283
  7. Shurin MR: Dendritic cells presenting tumor antigen. Can Immunol Immunother 43;158-164, 1996 https://doi.org/10.1007/s002620050317
  8. Moron G, Dadaclio G, Leclerc C: New tools for antig delivery to the MHC class I pathway. Trends Immunol 25;92-97, 2004 https://doi.org/10.1016/j.it.2003.11.008
  9. Hart DN: Dendritic cells: unique leukocyte populations, w control the primary immune response. Blood 90;3245-3287, 1997
  10. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagno Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovskv Zirvogel L: Dendritic cells directly trigger NK cell functio Cross-talk relevant in innate anti-tumor immune response vivo. Nature Medicine 5;405-411, 1999 https://doi.org/10.1038/7403
  11. Fields RC, Shimizu K, Mule JJ: Murine dendritic cells pu with whole tumor lysates mediate potent antitumor imm responses in vitro and in vivo. Proc Natl Acad Sci 95;9482-9487, 1998
  12. Inaba K. Young JW, Steinman RM: Direct activation of CD cytotoxic T lymphocytes by dendritic cells. J Exp Med 166; 182-194, 1987 https://doi.org/10.1084/jem.166.1.182
  13. Muller L, Provenzani C. Faul C. Pawelec G: Recognition chronic myelogenous leukemia cells by autologous T lymp cytes primed in vitro against the patient's dendritic cells. Br J Hematol 112;740-748, 2001 https://doi.org/10.1046/j.1365-2141.2001.02596.x
  14. Jean FF, Daniel GK, Margareta L, Catherine S, Timothy Nina B, Marie L: Characterization of the MHC class I cro presentation pathway for cell-associated antigens by hum dendritic cells. Blood 102;4448-4455, 2003 https://doi.org/10.1182/blood-2003-06-1801
  15. Palucka K, Bancherau J: Dendritic cells: a link between inn and adaptive immunity. J Clin Immunol 19;12-25, 1999 https://doi.org/10.1023/A:1020558317162
  16. Flamand V, Sornasse T, Thielemans K, Demanet C, Bak M, Bazin H, Tielemans F, Leo O, Urbain J. Moser M: Mu dendritic cells pulsed in vitro with tumor antigen induce mor resistance in vivo. Eur J Immunol 24;605-610, 1994 https://doi.org/10.1002/eji.1830240317
  17. Fong L, Engleman EG: Dendritic cells in cancer immunot rapy. Annul Rev Immunol 18;245-273, 2000 https://doi.org/10.1146/annurev.immunol.18.1.245
  18. Gong J. Chen D, Kashiwaba M, Kufe D: Induction of anti mor activity by immunization with fusions of dendritic carcinoma cells. Nat Med 3:558-561, 1997 https://doi.org/10.1038/nm0597-558
  19. Gong J, Avizan D, Chen D, Wu Z, Koido S, Kashiwaba Kufe D: Activation of antitumor cytotoxic T lymphocyte fusions of human dendritic cells and breast carcinoma ce Proc Natl Acad Sci 97;2715-2718, 2000
  20. Inaba K. Metlay JP, Crowley MT, Steinman RM: Dendritic pulsed with protein antigens in vitro can prime antigen-spec MHGrestricted T cells in situ. J Exp Med 172;631-640, 1990 https://doi.org/10.1084/jem.172.2.631
  21. Mayordomo JI, Zorina T, Storkus WJ. Zitvogel L, Cell C. Falo LD, Melief CJ. Ildstad ST, Kast WM, Deleo A: Bo marrow-derived dendritic cells pulsed with synthetic tum peotides elicit protective and therapeutic antitumour imm nity. Nat Med 1:1297-1302, 1995 https://doi.org/10.1038/nm1295-1297
  22. Lee JK, Lee MK, Yun YP: Acemannan purified from A vera induces phenotypic and functional maturation of im ture dendritic cells. Int Immunopharmacol 1:1275-1284, 2001 https://doi.org/10.1016/S1567-5769(01)00052-2
  23. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, Han Kim K, Eo SK, Lee CK: Cyclosporin A and tacrolimus, not rapamycin, inhibit MHC-restricted antigen presenta pathways in dendritic cells. Blood 105;3951-3955, 2005 https://doi.org/10.1182/blood-2004-10-3927
  24. Han S, Sung KH, Yim D, Lee S, Cho K, Lee CK, Ha N Kim K: Activation of murine macrophage cell line RA 264.7 by Korean Propolis. Arch Pharm Res 25:895-902, 2002 https://doi.org/10.1007/BF02977011
  25. Ivanovsca ND, Dimov VD, Pavlova S, Bankova VS, Pop SS, Immunomodulatorv action of propolis. VI. Anticom mentary activity of a water-soluble derivative. J Ethnophar macology 47;135-143, 1995 https://doi.org/10.1016/0378-8741(95)01273-G
  26. Harborne JB, Williams CA: Advances in flavonoid resea since 1992. Phytochemistry. 55;481-504, 2000 https://doi.org/10.1016/S0031-9422(00)00235-1
  27. Shen Z, Reznikoff G, Dranoff G, Rock KL: Cloned dendr cells can present exogenous antigens on both MHC clas and class II molecules. J Immunol 158;2723-2730, 1977
  28. Karttunen J, Sanderson S, Shastri N: Detection of rare an gen-presenting cells by the lacZ T-cell activation assay su gests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sc 89;6020-6024, 1992
  29. Harding CV, Collins D, Kanagawa O, Unanue ER: Lipo me-encapsulated antigens engender lysosomal processing f class II MHC presentation and cvtosolic processing for cl I presentation. J Immunol 147;2860-2863, 1991
  30. Porgador A, Yewdell JW, Deng Y, Bennink JR. Germain Localization, quantitation, and in situ detection of spec peptide-MHC class I complexes using monoclonal antibody. Immunity 6;715-726, 1997 https://doi.org/10.1016/S1074-7613(00)80447-1
  31. Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Prelinzer Lord EM: IL-3 enhances both presentation of exogeno particulate antigen in association with class I major histoco patibility antigen and generation of primary tumor-spec cytolytic T lymphocytes. J Immunol 160;5773-5780, 1998
  32. Larsson M, Fonteneau JF, Bhardwaj N: Dendritic cells surrect antigens from dead cells. Trends Immunol 22;14 148, 2001
  33. Yewdell JW, Norbury CC, Bennink JR: Mechanisms of ogenous antigen presentation by MHC class I molecules vitro and in vivo: implications for generating CD8+ T responses to infectious agents, tumors, transplants, and v cines. Adv Immunol 73;1-77, 1999 https://doi.org/10.1016/S0065-2776(08)60785-3
  34. Steinman RM, Inaba K, Turley S, Pierre P, Mellman I: tigen capture, processing, and presentation by dendritic ce recent cell biological studies. Hum Immunol 60;562-5 1999 https://doi.org/10.1016/S0198-8859(99)00030-0